Aditum Bio, the biotech investment firm co-founded by former Novartis CEO Joe Jimenez and Dr. Mark Fishman, former President of the Novartis Institutes for BioMedical Research (NIBR), is set to create a new portfolio company, Vitalli Bio. This company has been specially developed to produce new therapies for immunological disorders.
The formation of Vitalli Bio is to be completed with the in-licensing of a selective dual inhibitor of Interleukin-2-Inducible T-Cell Kinase (ITK) and Bruton’s Tyrosine Kinase (BTK) from Daewoong Pharmaceutical, expected to close in early May. This compound will be named VIT-801 and is projected to begin Phase 1 studies in 2023.
VIT-801, a groundbreaking dual-target inhibitor from Vitalli Bio, is revolutionizing the treatment of immune disorders. Unlike existing treatments, which typically only target a single cell type, VIT-801 simultaneously inhibits B cells, T cells and other immune cells, providing an unparalleled profile of efficacy.
Moreover, Vitalli Bio has the option to license earlier stage dual-target inhibitors developed by Daewoong, further expanding this innovative approach to immune disorder treatment.
Aditum Bio is revolutionizing the industry with its revolutionary translational medicine approach, and is thrilled to bring the promising compound VIT-801 into clinical trials for immunological disorders.
Co-Founder and Managing Director Joe Jimenez expressed his enthusiasm for the project, while Co-Founder and Chair of the Medical and Scientific Advisory Boards Dr. Mark Fishman highlighted the drug’s selective inhibition of various relevant immune cells, suggesting it could be a safe and effective treatment option for difficult-to-treat populations.
Aditum Bio is revolutionizing healthcare with the launch of their ninth company, Vitalli Bio. This innovative incubator model is designed to give large patient populations access to medicines that may not otherwise be developed.
By focusing on the translational phase of drug development, their spin-out model provides a nimble start-up culture with a dedicated team of managers backed by Aditum’s in-house experts in non-clinical pharmacology, CMC, regulatory affairs and clinical operations. This groundbreaking approach is transforming the way patients receive the medicines they need.
About Aditum Bio
At Aditum Bio, we’re on a mission to revolutionize public health. We specialize in accelerating the development of treatments for both common and rare diseases, harnessing the power of data, software and technology to drive innovation and reduce the time and cost of clinical trials.
Our goal is to identify promising treatments and spin them out into individual companies that can bring them through Phase II clinical trials, helping to make a real difference in the lives of patients everywhere.
About Daewoong Pharmaceutical
Established in 1945, Daewoong Pharmaceutical Co., Ltd. has grown to be a renowned South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals for both domestic and international markets.
With a strong and innovative in-house R&D and advanced manufacturing facilities, Daewoong provides a comprehensive healthcare solution to customers around the world. As part of its mission to become a global healthcare leader, Daewoong has opened branch offices and research centers in Asia and the United States, as well as forged strategic partnerships in more than 100 countries.
In 2022, Daewoong made a major stride in global expansion by signing a USD 923 million license agreement that allowed the use of its ‘Fexuclue’ medication for the treatment of gastroesophageal reflux disease in the Philippines and Ecuador.
On top of that, Daewoong made history by launching ‘Envlo’, the very first Korean-developed sodium glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes. Similarly, the company sealed an export contract for USD 84.36 million with Brazil and Mexico.